Hoth Therapeutics Inc (NASDAQ:HOTH) shares are surging after announcing development updates for its novel cancer therapeutic, HT-KIT.
- Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro.
- The researchers found that KIT protein expression, signaling and function were reduced.
- Treatment with HT-KIT prevented cancer cell growth and induced cell death over 72 hours.
- In a humanized mast cell leukemia mouse model, tumor growth and infiltration of other organs were reduced, and tumor cell death increased when HT-KIT induced frameshifted c-KIT mRNA.
- Hoth has filed several patent applications to protect this IP throughout the world.
- "Our next round of preclinical studies are underway. We are excited to utilize the results for our planned Pre-IND meeting with the FDA later this year," stated Robb Knie, Chief Executive Officer of Hoth.
- HT-KIT, a new molecular entity, was designated as an Orphan Drug to treat mastocytosis earlier in 2022.
- Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms to develop HT-KIT, a rare, aggressive cancer with a poor prognosis.
- Price Action: HOTH shares are up 111.1% at $1.30 during the market session on the last check Monday.
